テネシーにおける慢性リンパ性白血病の臨床試験
テネシー内の拠点で、慢性リンパ性白血病に関する17件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
被験者募集中観察研究
12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。